Search Results - "Slipek, Nicholas"

Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors by Webber, Beau R., Lonetree, Cara-lin, Kluesner, Mitchell G., Johnson, Matthew J., Pomeroy, Emily J., Diers, Miechaleen D., Lahr, Walker S., Draper, Garrett M., Slipek, Nicholas J., Smeester, Branden A., Lovendahl, Klaus N., McElroy, Amber N., Gordon, Wendy R., Osborn, Mark J., Moriarity, Branden S.

“…The fusion of genome engineering and adoptive cellular therapy holds immense promise for the treatment of genetic disease and cancer. Multiplex genome…”
Get full text

CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells by Kluesner, Mitchell G., Lahr, Walker S., Lonetree, Cara-lin, Smeester, Branden A., Qiu, Xiaohong, Slipek, Nicholas J., Claudio Vázquez, Patricia N., Pitzen, Samuel P., Pomeroy, Emily J., Vignes, Madison J., Lee, Samantha C., Bingea, Samuel P., Andrew, Aneesha A., Webber, Beau R., Moriarity, Branden S.

“…CRISPR-Cas9 cytidine and adenosine base editors (CBEs and ABEs) can disrupt genes without introducing double-stranded breaks by inactivating splice sites…”
Get full text

PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma by Smeester, Branden A., Slipek, Nicholas J., Pomeroy, Emily J., Laoharawee, Kanut, Osum, Sara H., Larsson, Alex T., Williams, Kyle B., Stratton, Natalie, Yamamoto, Kenta, Peterson, Joseph J., Rathe, Susan K., Mills, Lauren J., Hudson, Wendy A., Crosby, Margaret R., Wang, Minjing, Rahrmann, Eric P., Moriarity, Branden S., Largaespada, David A.

“…Osteosarcoma (OSA) is a heterogeneous and aggressive solid tumor of the bone. We recently identified the colony stimulating factor 1 receptor (Csf1r) gene as a…”
Get full text

A Pan-RNase Inhibitor Enabling CRISPR-mRNA Platforms for Engineering of Primary Human Monocytes by Laoharawee, Kanut, Johnson, Matthew J., Lahr, Walker S., Sipe, Christopher J., Kleinboehl, Evan, Peterson, Joseph J., Lonetree, Cara-lin, Bell, Jason B., Slipek, Nicholas J., Crane, Andrew T., Webber, Beau R., Moriarity, Branden S.

“…Monocytes and their downstream effectors are critical components of the innate immune system. Monocytes are equipped with chemokine receptors, allowing them to…”
Get full text

Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies by Skeate, Joseph G, Pomeroy, Emily J, Slipek, Nicholas J, Jones, Bryan J, Wick, Bryce J, Chang, Jae-Woong, Lahr, Walker S, Stelljes, Erin M, Patrinostro, Xiaobai, Barnes, Blake, Zarecki, Trevor, Krueger, Joshua B, Bridge, Jacob E, Robbins, Gabrielle M, McCormick, Madeline D, Leerar, John R, Wenzel, Kari T, Hornberger, Kathlyn M, Walker, Kirsti, Smedley, Dalton, Largaespada, David A, Otto, Neil, Webber, Beau R, Moriarity, Branden S

“…Cellular therapies for the treatment of human diseases, such as chimeric antigen receptor (CAR) T and natural killer (NK) cells have shown remarkable clinical…”
Get more information

Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K-AKT Signaling for the Treatment of Metastatic Osteosarcoma by Smeester, Branden A, Draper, Garrett M, Slipek, Nicholas J, Larsson, Alex T, Stratton, Natalie, Pomeroy, Emily J, Becklin, Kelsie L, Yamamoto, Kenta, Williams, Kyle B, Laoharawee, Kanut, Peterson, Joseph J, Abrahante, Juan E, Rathe, Susan K, Mills, Lauren J, Crosby, Margaret R, Hudson, Wendy A, Rahrmann, Eric P, Largaespada, David A, Moriarity, Branden S

“…We previously identified as an oncogenic driver of a subset of osteosarcomas using the ( ) transposon system. Here, we followed up by investigating the genetic…”
Get full text

SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis by Smeester, Branden A., Slipek, Nicholas J., Pomeroy, Emily J., Bomberger, Heather E., Shamsan, Ghaidan A., Peterson, Joseph J., Crosby, Margaret R., Draper, Garrett M., Becklin, Kelsie L., Rahrmann, Eric P., McCarthy, James B., Odde, David J., Wood, David K., Largaespada, David A., Moriarity, Branden S.

“…Semaphorins, specifically type IV, are important regulators of axonal guidance and have been increasingly implicated in poor prognoses in a number of different…”
Get full text

Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors by Webber, Beau R., Lonetree, Cara-lin, Kluesner, Mitchell G., Johnson, Matthew J., Pomeroy, Emily J., Diers, Miechaleen D., Lahr, Walker S., Draper, Garrett M., Slipek, Nicholas J., Smeester, Branden A., Lovendahl, Klaus N., McElroy, Amber N., Gordon, Wendy R., Osborn, Mark J., Moriarity, Branden S.

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade by Palmer, Douglas C, Webber, Beau R, Patel, Yogin, Johnson, Matthew J, Kariya, Christine M, Lahr, Walker S, Parkhurst, Maria R, Gartner, Jared J, Prickett, Todd D, Lowery, Frank J, Kishton, Rigel J, Gurusamy, Devikala, Franco, Zulmarie, Vodnala, Suman K, Diers, Miechaleen D, Wolf, Natalie K, Slipek, Nicholas J, McKenna, David H, Sumstad, Darin, Viney, Lydia, Henley, Tom, Bürckstümmer, Tilmann, Baker, Oliver, Hu, Ying, Yan, Chunhua, Meerzaman, Daoud, Padhan, Kartik, Lo, Winnie, Malekzadeh, Parisa, Jia, Li, Deniger, Drew C, Patel, Shashank J, Robbins, Paul F, McIvor, R Scott, Choudhry, Modassir, Rosenberg, Steven A, Moriarity, Branden S, Restifo, Nicholas P

“…Adoptive transfer of tumor-infiltrating lymphocytes (TIL) fails to consistently elicit tumor rejection. Manipulation of intrinsic factors that inhibit T cell…”
Get more information

Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair by Webber, Beau R, Johnson, Matthew J, Skeate, Joseph G, Slipek, Nicholas J, Lahr, Walker S, DeFeo, Anthony P, Mills, Lauren J, Qiu, Xiaohong, Rathmann, Blaine, Diers, Miechaleen D, Wick, Bryce, Henley, Tom, Choudhry, Modassir, Starr, Timothy K, McIvor, R Scott, Moriarity, Branden S

“…The reliance on viral vectors for the production of genetically engineered immune cells for adoptive cellular therapies remains a translational bottleneck…”
Get full text

Dose-dependent differential mRNA target selection and regulation by let-7a-7f and miR-17-92 cluster microRNAs by Shu, Jingmin, Xia, Zhilian, Li, Lihua, Liang, Ellen T., Slipek, Nicholas, Shen, Dawen, Foo, Jasmine, Subramanian, Subbaya, Steer, Clifford J.

“…MicroRNAs (miRNAs) are important players of post-transcriptional gene regulation. Individual miRNAs can target multiple mRNAs and a single mRNA can be targeted…”
Get full text

Abstract 1097: The miR-17-92 microRNA cluster plays a crucial role in osteosarcoma progression by Varshney, Jyotika, Slipek, Nicholas J., Osborne, John, Chang, Adrian, Sarver, Anne E., Cornax, Ingrid, O’Sullivan, Gerry M., Subramanian, Subbaya, Largaespada, David A.

“…Abstract Osteosarcoma is the most common primary bone malignancy that affects adolescents. Around 30% of patients with localized osteosarcoma and 70% of…”
Get full text

333 Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program by Palmer, Douglas, Webber, Beau, Patel, Yogin, Johnson, Matthew, Kariya, Christine, Lahr, Walker, Parkhurst, Maria, Gartner, Jared, Prickett, Todd, Lowery, Frank, Kishton, Rigel, Gurusamy, Devikala, Franco, Zulmarie, Vodnala, Suman, Diers, Miechaleen, Wolf, Natalie, Slipek, Nicholas, McKenna, David, Sumstad, Darin, Viney, Lydia, Henley, Tom, Bürckstümmer, Tilmann, Baker, Oliver, Hu, Ying, Yan, Chunhua, Meerzaman, Daoud, Padhan, Kartik, Lo, Winnie, Malekzadeh, Parisa, Jia, Li, Deniger, Drew, Patel, Shashank, Robbins, Paul, Scott McIvor, R, Choudhry, Modassir, Rosenberg, Steven, Moriarity, Branden, Restifo, Nicholas

“…BackgroundNeoantigen-specific T cells isolated from tumors have shown promise clinically but fail to consistently elicit durable tumor regression. Expression…”
Get full text

Dimethyl Fumarate Induces Cytoprotection and Inhibits Inflammation and Vaso-Occlusion in Transgenic Sickle Mice by Belcher, John D., Nguyen, Julia, Chen, Chunsheng, Abdulla, Fuad, Nguyen, Phong, Nguyen, Minh, Zhang, Ping, Xu, Pauline, Slipek, Nicholas J., Vercellotti, Gregory M.

“…Patients with sickle cell disease have unrelenting hemolysis leading to the release of hemoglobin and heme into the vasculature that promote oxidative stress,…”
Get full text

35 Targeted non-viral integration of large cargo in primary human T cells by CRISPR/Cas9 guided homology mediated end joining by Webber, Beau, Johnson, Matthew, Slipek, Nicholas, Walker Lahr, Qiu, Xiaohong, Rathmann, Blaine, Diers, Miechaleen, Wick, Bryce, McIvor, R Scott, Moriarity, Branden

“…BackgroundEngineered immune cells hold tremendous promise for the treatment of advanced cancers. As the scale and complexity of engineered cell therapies…”
Get full text